CG Oncology

Edit info

Founded: 2010

Location: Irvine, CA

Employee range: 11 - 50

Clinical stage: Clin3

Therapy area: Bladder cancer

Drug types: ONC

Lead product: GC0070

Funding: $105M Aug 2023; $120M E Nov 2022; $47M D Dec 2020; $22M C Mar 2019

Investors: ORI Capital, Longitude Capital, Decheng Capital, RA Capital Management, Acorn Bioventures, Malin Corporation, Ally Bridge Group, Sirona Capital, Foresite Capital, TCGX

cgoncology.com

linkedin.com

job board

Drug notes:

Also combo Clin2 bladder cancer, combo Clin1 bladder cancer

About:

CG Oncology is developing oncolytic immunotherapies to treat patients with advanced bladder cancer. Bladder cancer is the 4th most common form of cancer in men in the US. To address this CG is genetically engineering oncolytic immunotherapies. The therapy has a dual mechanism of action: first, the therapy infects and replicates inside tumor cells causing cell lysis. Secondly, the rupturing of cancer cells releases tumor-derived antigens that stimulates a systemic anti-tumor immune response. CG has 3 active clinical programs with their lead candidate, CG0070, showing remarkable efficacy in bladder cancer patients in their clinical trials.